Strategic crossing of biomass and harvest index—source and sink—achieves genetic gains in wheat

To accelerate genetic gains in breeding, physiological trait (PT) characterization of candidate parents can help make more strategic crosses, increasing the probability of accumulating favorable alleles compared to crossing relatively uncharacterized lines. In this study, crosses were designed to complement “source” with “sink” traits, where at least one parent was selected for favorable expression of biomass and/or radiation use efficiency—source—and the other for sink-related traits like harvest-index, kernel weight and grains per spike. Female parents were selected from among genetic resources—including landraces and products of wide-crossing (i.e. synthetic wheat)—that had been evaluated in Mexico at high yield potential or under heat stress, while elite lines were used as males. Progeny of crosses were advanced to the F4 generation within Mexico, and F4-derived F5 and F6 generations were yield tested to populate four international nurseries, targeted to high yield environments (2nd and 3rd WYCYT) for yield potential, and heat stressed environments (2nd and 4th SATYN) for climate resilience, respectively. Each nursery was grown as multi-location yield trials. Genetic gains were achieved in both temperate and hot environments, with most new PT-derived lines expressing superior yield and biomass compared to local checks at almost all international sites. Furthermore, the tendency across all four nurseries indicated either the superiority of the best new PT lines compared with the CIMMYT elite checks, or the superiority of all new PT lines as a group compared with all checks, and in some cases, both. Results support—in a realistic breeding context—the hypothesis that yield and radiation use efficiency can be increased by improving source:sink balance, and validate the feasibility of incorporating exotic germplasm into mainstream breeding efforts to accelerate genetic gains for yield potential and climate resilience

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

A stochastic model for the transmission dynamics of hepatitis B virus

In this paper, we formulate a stochastic model for hepatitis B virus transmission with the effect of fluctuation environment. We divide the total population into four different compartments, namely, the susceptible individuals in which the disease transmission rate is distributed by white noise, the acutely infected individuals in which the same perturbation occur, the chronically infected individuals and the recovered individuals. We use the stochastic Lyapunov function theory to construct a suitable stochastic Lyapunov function for the existence of positive solution. We also then establish the sufficient conditions for the hepatitis B extinction and the hepatitis B persistence. At the end numerical simulation is carried out by using the stochastic Runge–Kutta method to support our analytical findings

A sharp bound for the ergodic distribution of an inventory control model under the assumption that demands and inter-arrival times are dependent

In this study, a stochastic process which represents a single-item inventory control model with (s, S)-type policy is constructed when the demands of a costumer are dependent on the inter-arrival times between consecutive arrivals. Under the assumption that the demands can be expressed as a monotone convex function of the inter-arrival times, it is proved that this process is ergodic, and closed form of the ergodic distribution is given. Moreover, a sharp lower bound for this distribution is obtained. © 2014 Hanalioǧlu (Khaniyev) and Aksop

A Multiscale Model of Atherosclerotic Plaque Development: Toward a Coupling Between an Agent-Based Model and CFD Simulations

Computational models have been widely used to predict the efficacy of surgical interventions in response to Peripheral Occlusive Diseases. However, most of them lack a multiscale description of the development of the disease, which, in our hypothesis, is the key to develop an effective predictive model. Accordingly, in this work we present a multiscale computational framework that simulates the generation of atherosclerotic arterial occlusions. Starting from a healthy artery in homeostatic conditions, the perturbation of specific cellular and extracellular dynamics led to the development of the pathology, with the final output being a diseased artery. The presented model was developed on an idealized portion of a Superficial Femoral Artery (SFA), where an Agent-Based Model (ABM), locally replicating the plaque development, was coupled to Computational Fluid Dynamics (CFD) simulations that define the Wall Shear Stress (WSS) profile at the lumen interface. The ABM was qualitatively validated on histological images and a preliminary analysis on the coupling method was conducted. Once optimized the coupling method, the presented model can serve as a predictive platform to improve the outcome of surgical interventions such as angioplasty and stent deployment

Postharvest treatments of fresh produce

Postharvest technologies have allowed horticultural industries to meet the global demands of local and large-scale production and intercontinental distribution of fresh produce that have high nutritional and sensory quality. Harvested products are metabolically active, undergoing ripening and senescence processes that must be controlled to prolong postharvest quality. Inadequate management of these processes can result in major losses in nutritional and quality attributes, outbreaks of foodborne pathogens and financial loss for all players along the supply chain, from growers to consumers. Optimal postharvest treatments for fresh produce seek to slow down physiological processes of senescence and maturation, reduce/inhibit development of physiological disorders and minimize the risk of microbial growth and contamination. In addition to basic postharvest technologies of temperature management, an array of others have been developed including various physical (heat, irradiation and edible coatings), chemical (antimicrobials, antioxidants and anti-browning) and gaseous treatments. This article examines the current status on postharvest treatments of fresh produce and emerging technologies, such as plasma and ozone, that can be used to maintain quality, reduce losses and waste of fresh produce. It also highlights further research needed to increase our understanding of the dynamic response of fresh produce to various postharvest treatments

Novel pathogenic variants underlie SLC26A4-related hearing loss in a multiethnic cohort

WOS: 000413713100030PubMed ID: 28964290Objectives: The genetics of sensorineural hearing loss is characterized by a high degree of heterogeneity. Despite this heterogeneity, DNA variants found within SLC26A4 have been reported to be the second most common contributor after those of GJB2 in many populations. Methods: Whole exome sequencing and/or Sanger sequencing of SLC26A4 in 117 individuals with sensorineural hearing loss with or without inner ear anomalies but not with goiter from Turkey, Iran, and Mexico were performed. Results: We identified 27 unique SLC26A4 variants in 31 probands. The variants c.1673A > G (p.N558S), c.1708-1G > A, c.1952C > T (p.P651L), and c.2090-1G > A have not been previously reported. The p.N558S variant was detected in two unrelated Mexican families. Conclusion: A range of SLC26A4 variants without a common recurrent mutation underlies SLC26A4-related hearing loss in Turkey, Iran, and Mexico. (C) 2017 Elsevier B.V. All rights reserved.National Institutes of Health grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DC009645, R01DC012836]This work was supported by National Institutes of Health grants R01DC009645 and R01DC012836 to M.T